UPDATE: Morgan Stanley Reiterates on CVS/Caremark Following Acquisition of Coram
November 29, 2013 at 09:24 AM EST
In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on CVS/Caremark Corporation (NYSE: CVS ), but removed the $65.00 price target. In the report, Morgan Stanley noted, “CVS' $2.1 billion acquisition of Coram, Apria's home infusion business should help solidify CVS' position in the
